3,705 reports of this reaction
6.2% of all DARATUMUMAB reports
#1 most reported adverse reaction
PLASMA CELL MYELOMA is the #1 most commonly reported adverse reaction for DARATUMUMAB, manufactured by Janssen Biotech, Inc.. There are 3,705 FDA adverse event reports linking DARATUMUMAB to PLASMA CELL MYELOMA. This represents approximately 6.2% of all 59,976 adverse event reports for this drug.
Patients taking DARATUMUMAB who experience plasma cell myeloma should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PLASMA CELL MYELOMA is moderately reported among DARATUMUMAB users, representing a notable but not dominant share of adverse events.
In addition to plasma cell myeloma, the following adverse reactions have been reported for DARATUMUMAB:
The following drugs have also been linked to plasma cell myeloma in FDA adverse event reports:
PLASMA CELL MYELOMA has been reported as an adverse event in 3,705 FDA reports for DARATUMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
PLASMA CELL MYELOMA accounts for approximately 6.2% of all adverse event reports for DARATUMUMAB, making it one of the most commonly reported side effect.
If you experience plasma cell myeloma while taking DARATUMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.